| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Department of Obstetrics and Gynecology, Walter Reed Army Medical Center, Washington, DC; Departments of Obstetrics and Gynecology and Pathology, Oregon Health Sciences University, Portland, Oregon; and Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
Address reprint requests to: G Larry Maxwell, MD, 5217 Chevy Chase Parkway, Washington, D.C. 20015; E-mail: george.maxwell{at}na.amedd.army.mil.
OBJECTIVE: To compare the outcomes of patients with ovarian tumors of low malignant potential who had complete surgical staging with those who were unstaged to determine whether the rate of recurrence or survival was affected by surgical staging.
METHODS: A retrospective chart review was performed on 93 consecutive patients who had surgery for histologically confirmed tumors of low malignant potential between 1979 and 1997. Two cohorts of patients were identified: patients who had classic surgical staging (n = 48) versus those who were not staged (n = 45). Outcome data were recorded for patients and compared between the two groups.
RESULTS: Early stage (I or II) disease was diagnosed in 31 of 48 patients who had surgical staging and 42 of 45 patients who were not staged (P = .001). In 17% of patients their stage was upgraded on the basis of surgical staging, as a result of retroperitoneal involvement in only 6% of those cases (three of 48 staged patients). During the study interval, the frozen section diagnosis of low malignant potential tumor of the ovary was changed to a final diagnosis of invasive cancer in eight other patients. There were three recurrences and two deaths in both the staged and unstaged low malignant potential groups. The average duration of follow-up was 6.5 ± 4.2 years and was similar in the two groups. Overall 5-year survival was approximately 93% for all stages.
CONCLUSION: Survival and recurrence rates were not significantly different between staged and unstaged patients who had surgery for low malignant potential tumors of the ovary.
This article has been cited by other articles:
|
|
 |
|
  C. Poncelet, R. Fauvet, J. Boccara, and E. Darai Recurrence After Cystectomy for Borderline Ovarian Tumors: Results of a French Multicenter Study Ann. Surg. Oncol., April 1, 2006; 13(4): 565 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Leitao Jr and D. S. Chi Fertility-Sparing Options for Patients with Gynecologic Malignancies Oncologist, September 1, 2005; 10(8): 613 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fauvet, J. Boccara, C. Dufournet, C. Poncelet, and E. Darai Laparoscopic management of borderline ovarian tumors: results of a French multicenter study Ann. Onc., March 1, 2005; 16(3): 403 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Rao, E. Skinner, P. A. Gehrig, L. R. Duska, R. L. Coleman, and J. O. Schorge Surgical Staging of Ovarian Low Malignant Potential Tumors Obstet. Gynecol., August 1, 2004; 104(2): 261 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Camatte, P. Morice, D. Atallah, A. Thoury, P. Pautier, C. Lhomme, P. Duvillard, and D. Castaigne Clinical outcome after laparoscopic pure management of borderline ovarian tumors: results of a series of 34 patients Ann. Onc., April 1, 2004; 15(4): 605 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhu, X. Wang, Y. Ma, M. Rao, J. Glimm, and J. S. Kovach Detection of cancer-specific markers amid massive mass spectral data PNAS, December 9, 2003; 100(25): 14666 - 14671. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
